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Abstract
Cancer-associated fibroblasts (CAFs) are one of the main components of the stromal compartment in the tumor microen-
vironment (TME) and the crosstalk between CAFs and cancer cells is essential for tumor progression and aggressiveness. 
Cancer cells mediate an activation process, converting normal fibroblasts into CAFs, that are characterized by modified 
expression of many proteins and increased production and release of microvesicles (MVs), extracellular vesicles generated 
by outwards budding from the cell membrane. Recent evidence underlined that the uptake of CAF-derived MVs changes 
the overall protein content of tumor cells. In this paper, we demonstrate that tumor activated fibroblasts overexpress Galec-
tin-1 (Gal-1) and consequently release MVs containing increased levels of this protein. The uptake of Gal-1 enriched MVs 
by tumor cells leads to the upregulation of its intracellular concentration, that strongly affects cancer cell migration, while 
neither proliferation nor adhesion are altered. Accordingly, tumor cells co-cultured with fibroblasts silenced for Gal-1 have 
a reduced migratory ability. The present work reveals the key role of an exogenous protein, Gal-1, derived from activated 
fibroblasts, in cancer progression, and contributes to clarify the importance of MVs-mediated protein trafficking in regulat-
ing tumor-stroma crosstalk.
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Introduction
Tumor progression is not only dependent on cancer cell 
genetic and epigenetic alterations but it is strongly sup-
ported by the tumor reactive stroma (Valkenburg et  al. 
2018). Indeed, tumor mass is a complex network of cancer 
and stromal cells, of whose fibroblasts represent the main 
component. Upon stimulation by tumor cells, fibroblasts 
engage a trans-differentiation program converting them into 
their activated form, known as cancer-associated fibroblasts 
(CAFs) (Kalluri 2016). Remarkably, CAFs are involved in 
all the crucial steps of tumorigenesis, by sustaining neo-
angiogenesis (Orimo et al. 2005), the extracellular matrix 
(ECM) remodelling (Liu et al. 2019; Barbazán and Matic 
Vignjevic 2019) and the epithelial-to-mesenchymal transi-
tion (EMT) (Giannoni et al. 2010; Yu et al. 2014; Laberna-
die et al. 2017), thus promoting tumor cell migration and 
invasion, cancer stem cell (CSC) maintenance and metastatic 
dissemination (Santi et al. 2018). CAFs act also as a source 
of immunosuppressive molecules, thereby contributing to 
tumor immune escape (De Jaeghere et al. 2019). In addition, 
reciprocal metabolic symbiosis between CAFs and cancer 
cells supports invasive and drug resistant phenotypes in 
tumor cells and impairs antitumor immune responses, by 
altering the overall nutrient composition within the tumor 
microenvironment (TME) (Morandi et al. 2016; Comito 
et al. 2020).
The tumor-stroma crosstalk is mainly mediated by solu-
ble paracrine factors, cell–cell contacts and extracellular 
vesicles (EVs) trafficking (van Niel et al. 2018). Interest-
ingly, EVs trafficking acts either in an autocrine or paracrine 
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manner within the TME, thereby representing a key form of 
intercellular communication.
Although EVs comprise a great heterogeneous population 
of membrane vesicles, to date two types of EVs, with differ-
ent size, biogenesis and composition, have been described: 
microvesicles (MVs)/ectosomes (diameter from 100 nm to 
1 μm) and exosomes (diameter from 30 to 100 nm) (Cocucci 
and Meldolesi 2015). With regard to EV biogenesis, 
exosomes are intraluminal vesicles (ILVs), that originate 
from inward budding of endosomal membrane during the 
multivesicular endosome (MVE) maturation process, and are 
secreted as a consequence of MVEs fusion with cell surface. 
Conversely, MVs are generated by the outward budding and 
fission of the plasma membrane and are then released in the 
extracellular space. EVs usually contain various cargoes, 
including proteins, lipids, and nucleic acids (DNA, mRNAs 
and miRNAs). The specific composition of the EV content 
strictly depends on the cell type, the stimuli and molecular 
mechanisms regulating their biogenesis and release, and the 
physio-pathological state of the donor cells. Once released in 
the extracellular space, EVs target recipient cells and deliver 
their content which then alters the phenotypical and func-
tional properties of the targeted cells (van Niel et al. 2018).
Several recent findings underlined that CAFs are able to 
transfer EVs to tumor cells, providing significant evidence 
of EV-mediated back and forth exchange of factors between 
cancer and stromal cells within the TME (Shoucair et al. 
2020). It is noteworthy that the uptake of CAF-derived EVs, 
usually loaded with specific miRNAs, lncRNAs and pro-
teins, by recipient tumor cells strongly supports invasion 
and metastasis (Josson et al. 2015; Ren et al. 2018; Miki 
et al. 2018; Sun et al. 2019), and increases the proportion of 
CSCs (Hu et al. 2015). In addition, it has been demonstrated 
that patient-derived CAFs induce metabolic reprogramming 
of prostate and pancreatic tumor cells following EV uptake, 
ultimately promoting cancer cell growth. In particular, CAF-
derived EVs supply nutrient-deprived tumor cells with vari-
ous metabolites, including amino acids, lipids and tricarbo-
xylic acid (TCA) cycle intermediates, to upregulate their 
central carbon metabolism (Zhao et al. 2016). Moreover, 
recent findings underscored that miR-21, transferred from 
CAFs to recipient ovarian tumor cells through exosomes 
trafficking, suppresses tumor cell apoptosis and confers 
paclitaxel resistance (Au Yeung et al. 2016). Similarly, exo-
some-mediated transfer of miR-92a-3p from CAFs to colo-
rectal cancer cells promotes metastasis and 5-fluorouracil 
(5-FU)/ oxaliplatin (L-OHP) resistance (Hu et al. 2019).
Interestingly, a previous paper from our lab demonstrated 
that MVs transfer proteins and lipids essentially in a uni-
directional way, from CAFs to cancer cells. In particular, 
MV components have been found involved in increasing 
melanoma and prostate cancer cell proliferation and in 
inducing the reverse-Warburg phenotype in recipient tumor 
cells. Several CAFs proteins specifically transferred to can-
cer cells by this type of vehicle have been also identified. 
Among them, Galectin-1 (Gal-1) emerged as one of the most 
enriched protein in CAF-derived EVs (Santi et al. 2015).
Gal-1 is the best characterized member of the galectin 
family (Johannes et al. 2018). Galectins are a phylogeneti-
cally conserved family of lectins and they are composed by 
amino acid sequences of about 130 amino acids with the car-
bohydrate recognition domain responsible for β-galactoside 
binding (Barondes et al. 1994). Gal-1 is generally localized 
in cell nuclei and cytoplasm, but it also translocates to 
the intracellular and extracellular side of cell membranes. 
Indeed, it displays the characteristics of typical cytoplasmic 
proteins, as well as an acetylated N-terminus and lack of gly-
cosylation. It is noteworthy that Gal-1 can also be secreted in 
the extracellular matrices of various normal and neoplastic 
tissues (Cooper and Barondes 1990). Extracellular Gal-1 has 
been found altered in many cancer cell types (Thijssen et al. 
2015), including melanoma (Yazawa et al. 2015), ovarian 
(Zhang et al. 2014) and prostate cancers (Laderach et al. 
2013). Moreover, Gal-1 is often overexpressed in the reac-
tive stromal cells in the TME (Valach et al. 2012). Increased 
expression of Gal-1 correlates with a variety of processes in 
cancer progression, including the cellular aggregation/tumor 
formation, cancer metastatic spread, angiogenesis, and apop-
tosis (Liu and Rabinovich 2005; Cousin and Cloninger 2016; 
Orozco et al. 2018).
In the present work, we reveal that the intercellular trans-
port of Gal-1 from CAFs to tumor cells, mediated by MVs 
trafficking, leads to the upregulation of its steady state con-
centration in the recipient cancer cells and contributes to 
increase their migratory ability.
Materials and methods
Materials
Unless otherwise specified all reagents are from Sigma-
Aldrich. Opti-MEM, FluoroBrite™ DMEM, Lipo-
fectamine® transfection reagent, DAPI, CellTrace™ CFSE 
Cell Proliferation Kit and CellTracker™ Orange Dye are 
from Invitrogen™ Life Technologies. siRNAs for Gal-
1, RNase-free DNase set are from Qiagen. Sh-RNA vec-
tors are purchased from OriGene. RNA Nano Chip kit is 
from Agilent. PrimeScript RT reagent kit, ProteaseMAX™ 
Surfactant, Sequencing Grade Modified Trypsin are from 
Promega. Polyvinylidene difluoride (PVDF) membrane is 
from Millipore. Transwells are purchased from Euroclone. 
Anti-Gal-1 antibody is from Cell Signaling, anti-β-actin 
and anti-Integrin-β1 antibodies are from Santa Cruz Bio-
technology, anti-CD81 antibody is from BD Biosciences. 
The secondary antibodies enzyme horseradish peroxidase 
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(HRP)–conjugated are from Santa Cruz Biotechnology. All 
materials for SDS-PAGE and Clarity™ Western ECL sub-
strate are from Biorad. Culture-inserts (Dish 35 mm, high) 
are from ibidi®.
Cell cultures
Human prostate (DU145 and LNCaP), pancreatic (PANC-
1), and melanoma (A375) cancer cells were purchased from 
European Collection of Cell Culture (ECACC). Normal 
Human Fibroblasts (NHFs) used in our experiments were 
Human Dermal Fibroblasts (HDFs, from Invitrogen™ Life 
Technologies) and Human Prostate Fibroblasts (HPFs). 
HPFs were isolated from surgical explantation of patients 
who signed informed consent in accordance with the Ethics 
Committee of Azienda Ospedaliera Universitaria Careggi by 
Prof. Serni of Dipartimento di Medicina Sperimentale e Cli-
nica/Urology (Firenze, Italy) (Giannoni et al. 2010). No sig-
nificant differences were actually determined in the behavior 
of the two fibroblast lines. All cells were routinely cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM)—high 
glucose (4500 mg/L), except for LNCaP cells that were 
cultured in RPMI medium. Both media were supplemented 
with 10% fetal bovine serum (FBS, Euroclone), 2 mM glu-
tamine, 100 U/mL penicillin and 100 μg/mL streptomycin. 
Cells were incubated at 37 °C in a humidified atmosphere 
of 5%  CO2.
Conditioned media preparation and fibroblast 
activation
Tumor cells (DU145, A375, PANC-1) were incubated in 
growth medium with 1% of serum depleted by MVs and 
exosomes (EVs depleted FBS) for 24 h. Serum depletion was 
performed by centrifugation at 10.000×g for 1 h and subse-
quently at 100.000 × g for 90 min. After 24 h of incubation 
with tumor cells the medium was recovered, centrifuged at 
300 xg for 20 min to discard cell debris and used to culture 
fibroblasts for 24 h, obtaining their activated forms (A-HDFs 
and A-HPFs), superimposable to native CAFs (Giannoni 
et al. 2010).
Purification of membrane vesicles secreted 
by fibroblasts
Normal Human Fibroblasts (NHFs: HPFs or HDFs) or Acti-
vated Human Fibroblasts (AHFs: A-HPFs or A-HDFs) were 
cultured for 24 h in growth medium supplemented with 1% 
EVs depleted FBS. To isolate the MVs fraction, the medium 
was recovered and centrifuged at 300 xg for 10 min to dis-
card cells, at 2000 × g for 20 min to discard cell debris and 
finally at 10.000 × g for 1 h to pellet the MVs fraction. The 
pellet was resuspended in PBS and centrifuged again at 
10.000 × g for 1 h obtaining a purified MVs fraction. To 
isolate the exosomes fraction, the supernatant recovered 
after the 10.000 × g centrifugation was further centrifuged 
at 100.000 × g for 1 h and the pellet resuspended in PBS (Xu 
et al. 2015).
Western blot analysis
For electrophoresis and western blot (WB) analysis, 
MVs, exosomes or cell lysates were suspended in twofold 
concentrated Laemmli electrophoresis buffer (without 
β-mercaptoethanol and bromophenol blue) and assayed for 
protein content by the BCA method. Equal amount of total 
protein (20–40 μg) from each sample were additioned with 
β-mercaptoethanol and separated by SDS-PAGE. Subse-
quently, gels were electroblotted onto PVDF membranes. 
The blots were incubated with the selected primary antibody 
in order to evaluate specific protein content as indicated in 
the figures. After incubation with secondary antibodies, the 
blotting was developed by using the ECL plus immunode-
tection system.
Quantitative real time polymerase chain reaction 
(qPCR)
Quantitative PCR reactions were performed by using GoTaq 
qPCR master mix kit and the Mx3005P Stratagene system. 
Differential expressions of transcripts of interest were cal-
culated in relation to the h36B4 housekeeping transcript for 
cDNA. The primers for GAL-1 were:
Forward: 5’-TCG CCA GCA ACC TGA ATC TC-3’ 
Reverse: 5’-GCA CGA AGC TCT TAG CGT CA-3.
Transwell co‑culture system
Co-culture experiments were performed by using Transwell 
permeable supports with pore sizes of 0.4 µm or 8 µm. 
Tumor cells were seeded in 6-well plates, while NHFs were 
plated on the upper compartment of the Transwells in a 2:1 
ratio. After 24 h of incubation, protein content of cancer 
cells was analysed by western blot.
To verify that fibroblasts, seeded in the upper side of 
the 8 µm Transwells, do not traverse the filter and are not 
collected with tumor cells, NHFs were stained with 10 µM 
CFDA-SE in Hank’s Balanced Salt Solution (HBSS) for 
15 min at 37 °C. Then, NHFs were incubated with com-
plete DMEM for 1 h. After that, NHFs were harvested by 
trypsinization. Fibroblasts and tumor cells were co-cultured 
by using Transwell permeable supports with pore size of 
8.0 µm. Specifically, fibroblasts were seeded in the upper 
side of the insert, while tumor cells were seeded in the lower 
compartment. After 24 h of incubation, cells in the lower 
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compartment of the Transwell system were harvested by 
trypsinization, washed in PBS, and fixed in 3% paraform-
aldehyde. CFDA-SE fluorescence was analysed by flow 
cytometry. Tumor cells not co-cultured with NHFs were 
used as negative control. CFDA-SE-stained NHFs not co-
cultured with cancer cells were used as positive control.
siRNA cell transfection
Silencing with siRNA plasmid was performed with Lipo-
fectamine™ 2000, following manufacturer’s instructions. 
Cells were plated at 70% confluence and, before transfec-
tion, DMEM culture medium was removed and replaced 
with Optimem medium, lacking serum and antibiotics that 
could interfere with liposome formation. Solution con-
taining siRNA was added to solution with Lipofectamine 
and incubated at room temperature for 20 min, in order to 
promote liposome formation; then equal amounts of final 
solution were added to each plate. Optimem medium was 
removed after 4–6 h from transfection, as Lipofectamine 
could be slightly toxic for cells. Finally, cells were main-
tained in complete medium for 48 h and transfection effi-
ciency was evaluated through immunoblotting assays. Gal-1 
expression was silenced using four different pre-designed 
siRNAs directed against different regions of the Gal-1 
transcript (Qiagen, Hilden, siRNA3 = Hs_LGALS1_3 
HP, Cat. No. SI00035924; siRNA5 = Hs_LGALS1_5 Cat. 
No. HP SI02628269; siRNA6 = Hs_LGALS1_6 HP, Cat. 
No. SI03033947; siRNA7 = Hs_LGALS1_7 HP, Cat. No. 
SI03085453). siRNA7 was more effective in terms of down-
regulating Gal-1 expression on protein level compared to 
the others. The morphology of control and Gal-1 silenced 
DU145 cells was evaluated by taking photographs at ran-
domly chosen fields using the inverted microscope Nikon 
Eclipse TS100.
Sh‑RNA cell transfection
Lentiviral particles were generated by transfecting 293 T 
cells with a mix of 1/3 pGFP-C-shLenti construct (4 differ-
ent vectors for Gal-1), 1/3 delta Helper (carries sequence 
necessary for viral assembly of lentivirus) and 1/3 pVsVg 
(expresses the vesicular stomatitis virus envelop glycopro-
tein G pseudotype), using Lipofectamine™ 3000 Reagent 
and following manufacturer’s recommendations. 24 h post 
transfection, the medium was changed for fresh one. 24 h 
later, medium was changed again and viruses containing 
medium was collected, filtered through a 0.2 μm filter, and 
added on 40% confluent PANC-1 and NHFs cells seeded 
in 6 multi-well plates. This step was repeated 24 h later to 
perform a second infection. Five days after infection, expres-
sion of Green Fluorescent Protein (GFP) was verified by 
fluorescence microscopy and Gal-1 expression was evalu-
ated by WB analysis. The vectors used were:
#A AAC CTG GAG GCC ATC AAC TAC ATG GCAGC 
#B TCT GGT CGC CAG CAA CCT GAA TCT CAAAC 
#C GAC GGT GAC TTC AAG ATC AAA TGT GTGGC 
#D CCT TCC AGC CTG GAA GTG TTG CAG AGGTG 
The higher silencing has been found with vectors #A and 
#B for both PANC-1 and NHFs. Results referred to PANC-1 
and NHF cells silenced with vector #A.
The morphology of control and Gal-1 silenced PANC-1 
cells was evaluated by taking photographs at randomly 
chosen fields using the inverted microscope Nikon Eclipse 
TS100.
Proliferation assay
The proliferation of DU145 cells was evaluated using 
CFDA-SE probe. Tumor cells, control or silenced for 
Gal-1, were labeled with the dye at the concentration of 
2.5 μM. Then cells were cultured and after 24 and 48 h were 
detached, fixed in 3% paraformaldehyde and analysed by 
flow cytometry (BD FACSCanto II, BD Biosciences-US). 
The obtained fluorescence value was analysed by ModFit 
software to estimate the proliferation index.
The proliferation of GFP positive PANC-1 cells, control 
and silenced for Gal-1, was assessed by counting cells with 
Bürker’s chamber three times per condition 24 and 48 h after 
plating.
Adhesion assay
2 ×  105 cells were seeded in 35 mm dishes. After 0.5, 1, 2 
and 3 h, the number of adherent tumor cells was evaluated 
with crystal violet staining for 5 min at 37 °C. Fixed cells 
were washed with PBS and solubilized with 0,1 M Sodium 
Citrate, pH 4,2. The absorbance was evaluated at 595 nm.
Migration assay
PANC-1 migration was evaluated using Transwell systems, 
equipped with 8 μm pore polyvinylpirrolidone-free polycar-
bonate filters (6.5 mm diameter), coated with 1% fibronectin 
in 0.1% gelatin and stored at 4 °C. DU145 migration was 
evaluated with the same Transwell system but without coat-
ing. 5 ×  104 cells resuspended in 150 μL of DMEM with 1% 
EVs depleted FBS were seeded in the upper compartment of 
Transwells placed into 24-well culture dishes. In the lower 
compartment, 500 μl of DMEM with 1% EVs depleted FBS 
for PANC-1 cells and DMEM with 10% EVs depleted FBS 
for DU145 cells was added. Then, PANC-1 and DU145 con-
trol cells were treated with 50 μL of DMEM with 1% EVs 
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depleted FBS. Besides, tumor cells were treated with MVs 
isolated from normal fibroblasts (HDFs or HPFs) or from 
activated fibroblasts (A-HDFs or A-HPFs). Specifically, 
isolated MVs were resuspended in 50 μL of DMEM with 
1% EVs depleted FBS and then added to cell medium in the 
upper compartment of the Transwells. After 6 h for PANC-1 
cells and 16 h for DU145 cells, while the insert was still 
moist, the non-migratory cells were mechanically removed 
from the interior of the insert using a cotton swab. Migrated 
cells were fixed in cold methanol, labeled with DAPI and 
photographed by fluorescence microscopy (Leica TCS SP5). 
Chemotaxis was evaluated by counting the cells migrated to 
the lower surface of the filters as a mean of twenty randomly 
chosen fields.
Wound healing assay
PANC-1 and DU-145 cells were labeled with 5 μM Cell-
Tracker™ Orange Dye and co-cultured with GFP-NHF cells 
(control and silenced for Gal-1) in  Dish35mm,high Culture-
insert in ratio 1:1. The medium used for the co-culture was 
the FluoroBrite™ DMEM that does not interfere with fluo-
rescence. The day after the insert was removed and pictures 
at time 0 and 24 h were acquired with Leica FX 350 camera 
in a Leica AM 600 microscope, using these parameters: L5: 
ex BP 480/40, dichroic 505, em BP 527–30; N2.1 ex BP 
515/560, dichroic 565, em LP 590.
Statistical analysis
Data are presented in bar graphs as means ± SD from at least 
three independent experiments (unless specified). Statistical 
analysis of the data was performed by Student’s /t/-test or 
ANOVA followed by Tukey HSD test. /p/-values of ≤ 0.05 
were considered statistically significant. Single asterisk 
indicates a significant difference at /p/-value < 0.05, double 
asterisks indicate a significant difference at /p/-value < 0.01 
and triple asterisks indicate a significant difference at 
/p/value < 0.001.
Results
Gal‑1 is upregulated upon fibroblast activation 
and transferred to cancer cells using MVs as vehicles
The interplay between fibroblasts and cancer cells within 
the TME induces remarkable changes in the phenotypic 
features of both cell types, favoring cancer progression 
(Kalluri 2016). In particular, upon stimulation with pro-
inflammatory cytokines secreted by cancer cells, fibroblasts 
trans-differentiate in their activated form (CAFs) (Giannoni 
et al. 2010). One of the most important consequences of 
fibroblast activation is the increase in their ability to pro-
duce and secrete MVs, which are then uploaded in cancer 
cells, thereby playing an essential role in sustaining their 
proliferation. We previously identified various proteins that 
are specifically transferred from CAFs to cancer cells using 
MVs as vehicle (Santi et al. 2015). Here we focused our 
attention on one of these proteins, Gal-1, that is both one of 
the most present proteins in CAF-derived MVs and a protein 
known to be involved in many aspects of cancer progression 
(Liu and Rabinovich 2005).
Firstly, we found that NHFs upregulate both Gal-1 mRNA 
and protein levels when treated for 24 h with tumor condi-
tioned medium (t.c.m.) from tumor cells (Fig. 1A). Treat-
ment with t.c.m. converts normal fibroblasts into their acti-
vated forms (AHFs), that express the same protein markers 
and share the same cellular properties of native CAFs iso-
lated from tumors (Giannoni et al. 2010; Santi et al. 2015; 
Hu and Hu 2019).
All these experiments were performed using both Human 
Prostate Fibroblasts (HPFs) and Human Dermal Fibroblasts 
(HDFs), obtaining similar results. We then analysed the 
Gal-1 expression levels in EVs, i.e. MVs and exosomes, 
synthesized and secreted by normal and activated fibroblasts 
(Fig. 1B). Figure 1B clearly shows that Gal-1 is mostly pre-
sent in MVs respect to exosomes and its expression in MVs 
is increased upon fibroblast activation.
Overall, our data highlight that tumor secretome induces 
Gal-1 overexpression in activated fibroblasts as well as in 
their secreted MVs.
In order to dissect the mechanism of Gal-1 transfer from 
activated fibroblasts to cancer cells, we used Transwell sys-
tems with different pore sizes (0.4 or 8 μm). In this kind 
of co-culture, we observe the rapid activation, within few 
hours (data not shown), of fibroblasts into their activated 
counterpart due to cytokine-mediated crosstalk. Activated 
fibroblasts, in turn, increase their overall release of MVs 
containing Gal-1.
Figure  2A shows that only when fibroblasts and 
DU145 cancer cells were co-cultured in 8 μm Transwells 
we observed an upregulation of Gal-1 in recipient tumor 
cells. Hence, Gal-1 is not transferred by exosomes, that 
easily pass through 0.4 μm filters, nor Gal-1 derives from 
a de novo synthesis in cancer cells induced by fibroblast-
derived cytokines for the same reason. In addition, we 
found that NHFs are not able to pass the 8.0 μm filters 
and adhere to the lower compartment of Transwell sys-
tems where tumor cells are seeded, indicating that ana-
lysed cell lysates were specifically obtained from tumor 
cells. Overall these data underline that Gal-1 is trans-
ferred exclusively via MVs trafficking from fibroblasts 
to tumor cells. Analogous experiments were performed 
on other tumor cell lines obtaining similar results (data 
not shown).
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Finally we purified and characterized MVs and 
exosomes from AHFs using integrin-β1 and CD81 as 
specific markers of MVs and exosomes, respectively 
(Fig. 2B). Purified MVs and exosomes were then incu-
bated for 4 h with LNCaP cells, a prostate cancer cell 
line characterized by extremely low expression levels of 
Gal-1. Interestingly, Gal-1 expression levels are strongly 
increased in cell lysates from LNCaP cells treated with 
MVs, but only at a lower extent in tumor cells incubated 
with purified exosomes (Fig. 2C).
Exogenous Gal‑1 improves tumor cell migration
Gal-1 is widely reported as a protein able to influence sev-
eral aspects of tumor progression (Cousin and Cloninger 
2016). In order to assess its role in our experimental setting, 
we silenced Gal-1 expression in both DU145 and PANC-1 
cells (Fig. 3A, F).
Gal-1 silenced cells do not show differences nor in the 
cell proliferation rate (Fig. 3B, G) or in the adhesion proper-
ties (Fig. 3C, H), with respect to control cells. By contrast, 
Gal-1 silenced DU145 and PANC-1 cells exhibit distinct 
morphological traits when compared to their not-silenced 
counterpart. In particular, control cells display a higher 
Fig. 1  Gal-1 is overexpressed in activated fibroblasts and released 
into the extracellular milieu using MVs as vehicles. A Normal 
Human Fibroblasts (NHFs) were treated with t.c.m. from tumor 
cells for 24 h. qRT-PCR and WB analyses were performed to evalu-
ate Gal-1 mRNA and protein expression levels, respectively, in t.c.m. 
activated NHFs (AHFs) with respect to NHFs. Data shown repre-
sent mean + / − SD from three independent experiments (*p < 0.05; 
**p < 0.01). B NHFs and AHFs were incubated for 24 h with fresh 
DMEM supplemented with 1% EVs depleted FBS. Then, MVs and 
exosomes from NHFs and AHFs were isolated through differential 
centrifugation (see “Materials and methods”) and their total protein 
content analysed by SDS-PAGE and silver staining. The Gal-1 con-
tent was evaluated by WB with anti-Gal-1 antibody. 30 µg aliquots of 
proteins were loaded for each sample. The data shown are representa-
tive of at least three experiments with similar results
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number of cellular protrusion (Fig. 3D, I), that results in 
increased migratory potential. Indeed, Gal-1 silencing 
strongly impairs both DU145 and PANC-1 migratory abil-
ity (Fig. 3E, L).
Moreover we observed that purified MVs derived 
from AHFs (Fig. 4C, G) highly enhance both DU145 and 
PANC-1 migration when compared to control cells treated 
with DMEM with 1% FBS depleted of EVs (Fig. 4A, E). 
Interestingly, MVs purified from NHFs are less efficient in 
promoting DU145 and PANC-1 cell migration respectively 
(Fig. 4B, F).
To demonstrate that fibroblast-derived Gal-1 is directly 
implicated in tumor cell migration, we set up a wound heal-
ing assay in which PANC-1 and DU145 cells, labeled with 
CellTracker™ Orange Dye, were seeded in co-culture with 
AHFs, expressing GFP and stably silenced or not for Gal-1 
(Fig. 5A, D). PANC-1 and DU145 cells co-cultured with 
control AHFs result to have a greater migratory ability 
Fig. 2  Gal-1 is transferred to tumor cells using MVs as vehicles. 
A DU145 tumor prostate cells were seeded in a 6-well plate, while 
fibroblasts (NHFs) were plated on Transwells of different pore sizes 
(0.4 μm or 8 μm). The co-culture rapidly induces the fibroblasts acti-
vation. After 24 h cancer cells in the lower chamber were lysed and 
subjected to WB analysis. Quantification plot of Gal-1 expression, 
normalized using β-actin, was reported as fold increase respect to 
control (cancer cells in the lower chamber without fibroblasts plated 
on the filter). Data represent mean + / − SD from four independ-
ent experiments (**p < 0.01). B NHFs were activated for 24  h with 
t.c.m. Then, fresh growth medium with 1% FBS (depleted of EVs) 
was added for the following 24 h in order to collect fibroblast-derived 
MVs and exosomes. WB of AHF-derived MVs and exosomes, quan-
tified for protein content, was performed to characterize specific 
markers of MVs (integrin-β1) and exosomes (CD81). Equal amounts 
(20 µg) of each sample were analysed. C LNCaP cells were treated 
for 4  h with purified MVs or exosomes from A-HPF, resuspended 
in growth medium with 1% EVs depleted FBS. Then, the amount of 
Gal-1 in LNCaP cells was evaluated by WB analysis. The data shown 
are representative of at least three experiments with similar results
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compared to cancer cells co-cultured with Gal-1 silenced 
AHFs (Fig. 5B, E). To quantify the results of this experi-
ment, PANC-1 and DU145 cells present in the scratch at 
24 h were counted, excluding those placed at a distance 
less than 50 μm from the boundary of the scratch, to avoid 
considering cancer cells movement due to proliferation 
(Fig. 5C, F).
These findings evidence a novel mechanism exerted by 
CAFs to support tumor invasiveness through exogenous pro-
tein transfer via MVs.
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Discussion
Solid tumors are composed by cancer cells and tumor reac-
tive stroma (Wang et al. 2017). In the last decades the key 
role of stromal cells in promoting cancer aggressiveness 
has been the focus of several studies. Fibroblasts are the 
major stromal component in the TME and, in this context, 
they switch into their activated phenotype, namely CAFs. 
Cancer progression is strongly influenced by CAFs, that 
support ECM remodeling, angiogenesis, and inflammatory 
cells recruitment, via secretion of cytokines, chemokines, 
growth factors and EVs (Kalluri 2016; Barbazán and Matic 
Vignjevic 2019; Choe et al. 2013).
Santi and co-workers recently discovered a horizontal 
unidirectional transfer of proteins and lipids from CAFs to 
cancer cells, mostly mediated by MVs. They demonstrated 
that, even if structural proteins and glycolytic enzymes rep-
resent the 70% of total mass transferred from CAFs to cancer 
cells, the majority of these proteins are not enriched in tumor 
cells. By contrast, among the CAF-derived proteins specifi-
cally upregulated in recipient cells through MVs trafficking, 
Gal-1 resulted to be one of the most represented (Santi et al. 
2015). Therefore, in this paper we focus our attention on 
MV-mediated transfer of Gal-1 from CAFs to tumor cells 
in affecting the migratory abilities of recipient cancer cells.
Several studies investigated the role of stromal Gal-1 
upregulation in supporting tumor progression and aggres-
siveness, thus revealing its possible application as a novel 
therapeutic target for many types of cancer. In particular, 
Gal-1 has been found overexpressed in cancer-associated 
stromal cells of gastric adenocarcinoma and breast and pros-
tate tumors, correlating with increased tumor invasiveness 
and metastasis (van den Brûle et al. 2001; Jung et al. 2007; 
Bektas et al. 2010). Moreover, Tang and co-workers reported 
that CAF-derived Gal-1 strongly promotes angiogenesis in 
gastric cancer by sustaining endothelial cell proliferation, 
migration and tube formation (Tang et al. 2016). However, 
the molecular mechanisms by which high levels of exog-
enous Gal-1 in the stromal compartment affect cancer cell 
aggressiveness have not yet been completely clarified. Inter-
estingly, in vitro and in vivo studies on pancreatic ductal 
adenocarcinoma (PDAC) underlined that stromal Gal-1, 
that is highly overexpressed by stromal fibroblasts and pan-
creatic stellate cells, is directly secreted in the TME and 
consequently establishes paracrine crosstalk with epithelial 
tumor cells to further trigger proliferation and invasion of 
cancer cells, enhance angiogenesis and inhibit immune cell 
infiltration (Xue et al. 2011; Martínez-Bosch et al. 2014; 
Orozco et al. 2018).
In the present paper, we demonstrate that Gal-1 expres-
sion in various cancer cell types can be upregulated through 
its highly efficient transfer via-MVs from activated fibro-
blasts to tumor cells, rather than being directly secreted in 
the extracellular environment by stromal cells or being mod-
ulated by the more common intercellular signaling mediated 
by paracrine factors.
It is noteworthy that protein transfer via EVs from CAFs 
to cancer cells has not been largely addressed, since the 
majority of the studies focused on the role of EV-mediated 
transfer of miRNAs within the TME (Shoucair et al. 2020). 
Notably, we show that the conversion of normal fibroblasts 
into their activated counterparts, upon stimulation with 
cytokines in the tumor conditioned media from cancer 
cells, causes the upregulation of Gal-1 expression levels, 
both in their intracellular compartment and in their secreted 
MVs (Fig. 1). Indeed, the protein content of EVs is strictly 
dependent on the cell type they originate from, the biogen-
esis and the stimuli driving their release (Zaborowski et al. 
2015).
Despite MVs trafficking is currently emerging as a criti-
cal mediator of intercellular communication in the context 
of the tumor-stroma crosstalk (Muralidharan-Chari et al. 
2010; Menck et al. 2020), its function is still poor defined. 
For instance, most studies concerning EVs transfer during 
cancer progression focused on exosomes (Dai et al. 2020) or 
mixed vesicle populations and it is still largely unclear which 
sub-population of EVs is responsible for a given physio-
pathological effect (van Niel et al. 2018; Han et al. 2019; 
Maacha et al. 2019). The reason for such a lack of informa-
tion regarding MV trafficking is mainly due to the challenges 
encountered during the selective isolation of specific sub-
species of vesicles. Indeed, although numerous reports have 
been published on comparative methods for EV isolation, 
including density gradient ultracentrifugation, size exclusion 
chromatography, precipitation via volume-excluding poly-
mers, flow-cytometry, and high pressure liquid chromatogra-
phy, we are still far from having pure isolation of exosomes 
and MVs (Konoshenko et al. 2018; Théry et al. 2018). In this 
context, we checked the purity of EV separation, obtained 
Fig. 3  Gal-1 enhances cell migration but not proliferation nor adhe-
sion of DU145 and PANC-1 cells. Cell proliferation, cell adhe-
sion, morphology and cell migration were evaluated on DU145 and 
PANC-1 cells silenced or not for Gal-1 expression. A WB analysis 
of Gal-1 expression of control and silenced DU145 cells. Silencing 
has been achieved by siRNA (see “Materials and methods”). B Pro-
liferation index of control and silenced DU145 cells using CFDA-SE 
assay (see “Materials and methods”). C Cell adhesion assay of con-
trol and silenced DU145 cells. D Cell morphology of control and 
Gal-1 silenced DU145 cells. Scale bar = 50 µm. E Migration assay of 
control and silenced DU145 cells. F WB analysis of Gal-1 expression 
of control and silenced PANC-1 cells. Silencing has been achieved 
by shRNA (see “Materials and methods”). G Proliferation index 
of control and silenced PANC-1 cells using Burker’s chamber cell 
count. H Cell adhesion assay of control and silenced PANC-1 cells. 
I Cell morphology of control and Gal-1 silenced PANC-1 cells. Scale 
bar = 50 µm. L Migration assay of control and silenced PANC-1 cells. 
For all kind of tests data represent mean + / − SD from at least three 
independent experiments (**p < 0.01; ***p < 0.001)
◂
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through differential centrifugation, by using Integrin β1 
and CD81 as markers of MVs and exosomes, respectively 
(Fig. 2) (Santi et al. 2015).
Remarkably, we highlight that the specific intercellular 
trafficking of MVs from activated fibroblasts to cancer cells 
mediates the transfer of Gal-1 to the latter. In fact, when 
tumor cells are co-cultured with fibroblasts in Transwell 
systems with 0.4 μm pore size, that allow the free passage 
of exosomes and paracrine soluble factors released by 
fibroblasts but not the transfer of MVs, Gal-1 expression 
levels are not increased in cancer cells. Conversely, when 
using Transwell systems with 8  μm pore size, freely 
permeable to MVs, in tumor cells/fibroblasts co-culture 
settings, Gal-1 expression is upregulated in tumor 
recipient cells (Fig. 2). In addition, LNCaP cells, which are 
characterized by endogenous extremely low levels of Gal-1, 
treated with MVs purified from AHFs display an appreciable 
increase in the expression levels of Gal-1, when compared 
to cells treated with purified exosomes from AHFs (Fig. 2). 
These results further indicate that Gal-1 is transferred 
from activated fibroblasts to cancer cells specifically via 
MVs. This finding is consistent with our previous evidence 
highlighting that MVs are more efficient than exosomes in 
transferring proteins to recipient cells (Santi et al. 2015).
Along with Gal-1 upregulation in the tumor-associated 
stromal compartment, Gal-1 has been found overexpressed 
Fig. 4  DU145 and PANC-1 migration is strongly enhanced by MVs 
derived from activated fibroblasts. Boyden chamber migration assay 
was performed on DU145 and PANC-1 cells treated or not with MVs 
derived from both normal fibroblasts and activated fibroblasts. A–C 
DU145 cells cultured in the presence of: A DMEM supplemented 
with 1% FBS depleted of EVs (control); B MVs purified from NHFs; 
C MVs purified from AHFs (see “Materials and methods”). D Quan-
tification of DU145 cell migratory capacity expressed as fold increase 
of migrated cells respect to control. E–G PANC-1 cells cultured in 
the presence of: E DMEM supplemented with 1% FBS depleted of 
EVs (control); F MVs purified from NHFs; G MVs purified from 
AHFs (see “Materials and methods”). H Quantification of PANC-1 
cell migratory capacity expressed as fold increase of migrated cells 
respect to control. Scale bar = 50  µm. Data represent mean + / − SD 
from three independent experiments (**p < 0.01)
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Fig. 5  Exogenous Gal-1 derived by activated fibroblasts promotes 
migration in tumor cells. A, D Stable Gal-1 silencing in AHFs was 
evaluated by WB analysis. β-actin was used for normalization. B 
Wound healing assay of DU145 cells (labeled with Cell Tracker™ 
Orange Dye) in co-culture with AHFs (GFP positive) silenced or not 
for Gal-1 expression. Scale bar 200 µm. C Mean of DU145 cells pre-
sent in the wound after 24  h, without considering cells placed at a 
distance of less than 50 μm from both sides of the scratch. E Wound 
healing assay of PANC-1 cells (labeled with Cell Tracker™ Orange 
Dye) in co-culture with AHFs (GFP positive) silenced or not for 
Gal-1 expression. Scale bar 200  µm. F Mean of PANC-1 cells pre-
sent in the wound after 24  h, without considering cells placed at a 
distance of less than 50 μm from both sides of the scratch. Data rep-
resent mean + / − SD from three independent experiments (*p < 0.05)
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also in cancer cells. Indeed, it has been reported that the 
overexpression of this protein in different tumor types corre-
lates with several processes of cancer malignancy, including 
tumor cell proliferation, migration, invasion and T cell acti-
vation (Spano et al. 2010; Kim et al. 2012; Noda et al. 2017), 
and it is associated with patient worse prognosis (Kim et al. 
2013; Chen et al. 2014; Yazawa et al. 2015). Therefore, we 
evaluate the biological effects of Gal-1 upregulation in our 
cancer cell models. To this aim, we silenced Gal-1 expres-
sion in two different cancer cell lines: DU145, a prostatic 
cancer cell line, and PANC-1, a pancreatic adenocarcinoma 
cell line. This latter represents a kind of tumor characterized 
by a high degree of stromal infiltration and fibrosis (von 
Ahrens et al. 2017). In DU145 as well as in PANC-1 cells, 
Gal-1 downregulation does not affect cell proliferation nor 
cell adhesion rate, while strongly impairs cell migration 
(Fig. 3). Accordingly, it has been demonstrated that Gal-1 
is highly overexpressed in castrate resistant prostate cancer 
(CRPC) and its knockdown significantly decreases prostate 
cancer cell migration and invasion (Shih et al. 2018). Simi-
larly, Gal-1 plays a pivotal role in PDAC progression, by 
inducing tumor growth, immune evasion and angiogenesis 
(Berberat et al. 2001; Roda et al. 2009; Martinez-Bosch et al. 
2018). Overall, besides the already described role of Gal-1 
overexpression in the stromal compartment of pancreatic 
and prostate tumors (van den Brûle et al. 2001; Orozco et al. 
2018), the upregulation of this protein in cancer cells is cru-
cial for tumor malignancy.
MVs recently emerged as important vehicles for the 
transfer of bioactive molecules within the TME. Indeed, the 
deliver of MV cargoes in tumor cells strongly alters their 
functional characteristics. However, the majority of these 
studies investigated the effects of tumor-derived MVs in 
modulating the behavior of either tumor cells, via autologous 
cell–cell communication (Al-Nedawi et al. 2008; Arendt 
et al. 2014), or neighboring TME cells, including endothelial 
cells (Kawamoto et al. 2012), fibroblasts (Jiang et al. 2019) 
and immune cells (Baj-Krzyworzeka et al. 2007; Cui et al. 
2018), through heterologous cell–cell communication. 
Conversely, the effects of CAF-derived MVs in cancer 
progression still need to be elucidated. Since Gal-1 plays a 
fundamental role in promoting migration of tumor cells (Zhu 
et al. 2016; Orozco et al. 2018), we then investigated whether 
MV-derived Gal-1 released from activated fibroblasts affects 
the migratory ability of DU145 and PANC-1 tumor cells.
It is noteworthy that MVs purified from normal fibro-
blasts are weakly able to increase DU145 migration 
respect to control, while MVs purified from activated 
fibroblasts strongly increase the migratory ability of 
tumor cells (Fig. 4). This effect correlates with enhanced 
Gal-1 expression in MVs derived from activated fibro-
blasts when compared to those derived from their normal 
counterpart (Fig. 1). This finding is consistent with our 
previous results, indicating that activated fibroblasts have 
a greater ability to transfer bioactive molecules via MVs-
trafficking to recipient tumor cells, when compared to their 
not-activated counterpart (Santi et al. 2015).
Finally, we demonstrate that in a co-culture wound heal-
ing assay, Gal-1 stably silenced AHFs are far less efficient 
in promoting PANC-1 and DU145 cell migration than wild 
type AHFs, further substantiating the biological impor-
tance of exogenous Gal-1 in cancer cell migration (Fig. 5).
Accordingly, several studies highlight the key role of 
CAF-derived EVs in enhancing the migratory and invasive 
potential of recipient cancer cells. For example, Leca and 
co-authors revealed an increase in the migratory abilities 
of PDAC cells after the uptake of CAF-derived ANXA6 
positive EVs (Leca et al. 2016). Similarly, EVs secreted 
by fibroblasts support colorectal cancer cell proliferation, 
probably through the transfer of amphiregulin (Oszvald 
et al. 2020), and FAK signaling in CAFs regulates the 
abilities of CAF-derived exosomes to induce breast can-
cer cell migration and ultimately metastasis (Wu et al. 
2020). Coherently, Luga and co-workers reported that 
fibroblast-secreted exosomes drive breast cancer cell inva-
sion through Wnt-planar cell polarity autocrine signaling 
(Luga et al. 2012). In addition, it has been demonstrated 
that CAF-derived EVs promote the migration and invasion 
of oral squamous cell carcinoma (Dourado et al. 2019). 
However, the importance of the specific transfer of pro-
teins via MVs in affecting migration of recipient cells has 
not been largely addressed so far.
Overall, our work highlights the fundamental role of the 
MVs-mediated trafficking of specific CAF proteins in the 
crosstalk, within TME, between cancer and stromal cells, 
thereby providing specific phenotypic advantages to tumor 
cells. In our case, exogenous Gal-1, derived from MVs 
released by CAFs, increases cell motility in two different 
tumor cell lines. To the best of our knowledge this is the 
first example showing that an exogenous protein trans-
ferred from CAFs to cancer cells using MVs as vehicles 
may profoundly affect cancer progression.
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